|
VMA21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.23539999999867E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.240820E-04 |
| Normal-vs-Stage2 |
2.703800E-02 |
| Normal-vs-Stage3 |
2.49769999999261E-05 |
| Normal-vs-Stage4 |
1.54811999999449E-05 |
| Stage1-vs-Stage2 |
1.621380E-01 |
| Stage1-vs-Stage3 |
2.738600E-01 |
| Stage1-vs-Stage4 |
1.456380E-01 |
| Stage2-vs-Stage3 |
4.878400E-02 |
| Stage2-vs-Stage4 |
2.046300E-02 |
| Stage3-vs-Stage4 |
5.732600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.01949999999451E-05 |
| Normal-vs-AfricanAmerican |
4.480500E-02 |
| Normal-vs-Asian |
4.357500E-03 |
| Caucasian-vs-AfricanAmerican |
2.598200E-01 |
| Caucasian-vs-Asian |
1.903420E-01 |
| AfricanAmerican-vs-Asian |
8.835600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.437570E-04 |
| Normal-vs-Female |
7.84890000000704E-05 |
| Male-vs-Female |
9.549200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.85365999999521E-05 |
| Normal-vs-Age(41-60Yrs) |
3.95349999999794E-05 |
| Normal-vs-Age(61-80Yrs) |
4.556600E-04 |
| Normal-vs-Age(81-100Yrs) |
1.464980E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.118400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.859400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.453400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.658400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.143200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.177400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.628200E-02 |
| Classical-VS-Follicular |
6.399000E-01 |
| Classical-VS-Other |
3.727400E-01 |
| Classical-VS-Normal |
4.368100E-04 |
| Tall-VS-Follicular |
4.258200E-02 |
| Tall-VS-Other |
8.597800E-01 |
| Tall-VS-Normal |
1.63825999999201E-05 |
| Follicular-VS-Other |
3.598400E-01 |
| Follicular-VS-Normal |
1.984710E-03 |
| Other-VS-Normal |
4.194400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.54553999999196E-05 |
| Normal-vs-N1 |
1.53159999999319E-05 |
| N0-vs-N1 |
9.306300E-02 |
|
|
